<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2015-9-54-61</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-246</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОНТРАЦЕПЦИЯ И ЭНДОКРИННАЯ ГИНЕКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CONTRACEPTION AND ENDOCRINE GYNECOLOGY</subject></subj-group></article-categories><title-group><article-title>Комплексная оценка эффективности, переносимости и безопасности комбинированного гормонального контрацептива третьего поколения</article-title><trans-title-group xml:lang="en"><trans-title>Comprehensive assessment of efficacy, tolerability and safety of a third-generation combined hormonal contraceptive</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Межевитинова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mezhevitinova</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурлев</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Burlev</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Набиева</surname><given-names>К. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Nabiyeva</surname><given-names>K. R.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ильясова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ilyasova</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иноземцева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Inozemtseva</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России, Москва<country>Россия</country></aff><aff xml:lang="en">V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2015</year></pub-date><volume>0</volume><issue>9</issue><fpage>54</fpage><lpage>61</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Межевитинова Е.А., Бурлев В.А., Набиева К.Р., Ильясова Н.А., Иноземцева Е.А., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Межевитинова Е.А., Бурлев В.А., Набиева К.Р., Ильясова Н.А., Иноземцева Е.А.</copyright-holder><copyright-holder xml:lang="en">Mezhevitinova E.A., Burlev V.A., Nabiyeva K.R., Ilyasova N.A., Inozemtseva E.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/246">https://www.med-sovet.pro/jour/article/view/246</self-uri><abstract><p>В настоящее время вопросы планирования беременности и ее отсрочки без последствий для здоровья приобретают особую остроту. Комбинированные гормональные контрацептивы служат одним из наиболее эффективных методов предотвращения нежелательной беременности, обеспечивая высокую контрацептивную надежность, доступность и простоту применения, обратимость эффектов и безопасность, а также лечебное и профилактическое действие при различных состояниях. Однако, по данным Госкомстата России, в нашей стране гормональную контрацепцию используют только 13,4% женщин (2009 г.). Связано это с настороженностью как пациенток, так и врачей в отношении побочных эффектов гормональных контрацептивов и приемлемости метода в целом. На базе научно-поликлинического отделения ФГБУ «НЦАГиП им. В.И. Кулакова» Минздрава России было проведено исследование с участием 75 пациенток в возрасте от 18 до 49 лет, обратившихся на прием для подбора современных методов контрацепции. На основании 9-месячного изучения влияния комбинированного гормонального контрацептива, содержащего эстрадиола валерат и диеногест, можно утверждать, что данный препарат обладает высокой контрацептивной эффективностью и хорошей приемлемостью.</p></abstract><trans-abstract xml:lang="en"><p>Planning for pregnancy and delaying pregnancy without health consequences are especially challenging today. Combined hormonal contraceptives are among the most effective methods of preventing unwanted pregnancies, providing high contraceptive reliability, availability and ease of use, safety and reversibility, as well as therapeutic and preventive action in various states. However, according to the State Statistics Committee of Russia, hormonal contraception is used only by 13.4% of women (2009) in this country. This is caused by suspicions both of patients and physicians about side effects of hormonal contraceptives and feasibility of the method in general.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>комбинированная гормональная контрацепция</kwd><kwd>диеногест</kwd><kwd>эстрадиола</kwd><kwd>валерат</kwd><kwd>приемлемость контрацептивов</kwd><kwd>лечебные эффекты гормональных контрацептивов</kwd><kwd>межменструальные кровянистые выделения</kwd><kwd>Клайра</kwd><kwd>combined hormonal contraception</kwd><kwd>dienogest</kwd><kwd>estradiol vale</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Прилепская В.Н., Межевитинова Е.А. с соавт. Гормональная контрацепция, 2011.</mixed-citation><mixed-citation xml:lang="en">Прилепская В.Н., Межевитинова Е.А. с соавт. Гормональная контрацепция, 2011.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Прилепская В.Н. Лечебные возможности гормональной контрацепции. Русский медицинский журнал, 1999; 1, 2: 1-5.</mixed-citation><mixed-citation xml:lang="en">Прилепская В.Н. Лечебные возможности гормональной контрацепции. Русский медицинский журнал, 1999; 1, 2: 1-5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Информационное письмо для практических врачей АГЭ 2011 г.</mixed-citation><mixed-citation xml:lang="en">Информационное письмо для практических врачей АГЭ 2011 г.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta SK, Gupta N, Suman P et al. Zonapellucida-based contraceptive vaccines for human and animal utility. J Reprodlmmunol. 2011 Mar: 88(2): 240-246.</mixed-citation><mixed-citation xml:lang="en">Gupta SK, Gupta N, Suman P et al. Zonapellucida-based contraceptive vaccines for human and animal utility. J Reprodlmmunol. 2011 Mar: 88(2): 240-246.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestra-diol 15 microg. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 9-15.</mixed-citation><mixed-citation xml:lang="en">The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestra-diol 15 microg. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 9-15.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74(6): 451-457.</mixed-citation><mixed-citation xml:lang="en">Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74(6): 451-457.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Palacios S, Wildt L, Parke S et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010; 149: 57-62.</mixed-citation><mixed-citation xml:lang="en">Palacios S, Wildt L, Parke S et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010; 149: 57-62.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Archer DF, Lasa IL. Tailoring combination oral contraceptives to the individual woman. J Womens Health (Larchmt). 2011 Jun; 20 (6): 879-891.</mixed-citation><mixed-citation xml:lang="en">Archer DF, Lasa IL. Tailoring combination oral contraceptives to the individual woman. J Womens Health (Larchmt). 2011 Jun; 20 (6): 879-891.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE, Mayer AP et al. Hormonal contraception update. Mayo Clin Proc 2006; 81: 949-954.</mixed-citation><mixed-citation xml:lang="en">David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE, Mayer AP et al. Hormonal contraception update. Mayo Clin Proc 2006; 81: 949-954.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nahum GG, Parke S, Efficacy and tolerability of a new oral contraceptivecontaining estradiol and dienogest ObstetGynecol 2008; 111(4 Suppl.).</mixed-citation><mixed-citation xml:lang="en">Nahum GG, Parke S, Efficacy and tolerability of a new oral contraceptivecontaining estradiol and dienogest ObstetGynecol 2008; 111(4 Suppl.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
